Dongwha Pharm Receives Approval for Phase 2 Clinical Trial of COVID-19 Treatment

[Asia Economy Reporter Cho Hyun-ui] Dong Wha Pharm announced on the 24th that the Ministry of Food and Drug Safety has approved the Phase 2 clinical trial plan for the novel coronavirus disease (COVID-19) treatment 'DW2008S'.

This clinical trial will evaluate the efficacy and safety of DW2008S, which is being developed as an asthma treatment, in patients with moderate COVID-19.

DW2008S demonstrated safety and tolerability in clinical trials conducted on healthy individuals during its development as an asthma treatment, and a Phase 2 clinical trial for asthma treatment is currently underway.

Dong Wha Pharm stated, "In addition to DW2008S, we are conducting two studies under the support of the Ministry of Science and ICT government project: a GLP toxicity test for non-clinical research using the single active ingredient of DW2008S, and a new drug candidate discovery study using novel derivative substances."